Clinical trial
Optimizing Response in Psychosis Study
NCT00314327 · Northwell Health, Other · Terminated
Key facts
| NCT number | NCT00314327 |
|---|---|
| Title | Optimizing Response in Psychosis Study |
| Official title | Optimizing Response in Psychosis Study |
| Acronym | ORP |
| Lead sponsor | Northwell Health, Other |
| Collaborators | The Zucker Hillside Hospital National Alliance for Research on Schizophrenia and Depression |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified |
| Intervention type | Drug |
| Interventions | long-acting injectable risperidone |
| Enrollment | 1 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Apr 13, 2006 |
| Last update posted | May 16, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: